Death Receptor Signaling in Cancer Therapy

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)

Volume 16, 12 Issues, 2016

Download PDF Flyer

Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

Death Receptor Signaling in Cancer Therapy

Anti-Cancer Agents in Medicinal Chemistry, 3(4): 253-262.

Author(s): Simone Fulda and Klaus-Michael Debatin.

Affiliation: University Children's Hospital, Prittwitzstr. 43, D-89075 Ulm, Germany.


Apoptosis, the cells intrinsic death program, is a key regulator of tissue homeostasis. An imbalance between cell death and proliferation may result in tumor formation. Also, killing of cancer cells by cytotoxic therapies, such as chemotherapy, γ-irradiation or ligation of death receptors is predominantly mediated by triggering apoptosis in target cells. Death receptor signaling pathways have been implied to contribute to the efficacy of cancer therapy. Failure to undergo apoptosis in response to anticancer therapy may lead to resistance. Understanding the molecular events that regulate apoptosis induced by anticancer therapy and how cancer cells evade apoptosis may provide new opportunities for drug development. Thus, novel strategies targeting tumor cell resistance will be based on insights into the molecular mechanisms of cell death.


apoptosis, death receptor, cd95, drugs, resistance.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 3
Issue Number: 4
First Page: 253
Last Page: 262
Page Count: 10
DOI: 10.2174/1568011033482404
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science